Table 5. Clinical, biological, genetic and therapeutic characteristics of sporadic colorectal cancer (sCRC) patients (n=74) with an impact on progression-free survival (PFS) and overall survival (OS).
| Variable | PFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|---|
| N | % 2-year PFS | Univariate analysis |
Multivariate analysis |
HR (95% CI) |
% 2-year OS | Univariate analysis |
Multivariate analysis |
HR (95% CI) |
|
| Age | |||||||||
| <72 years | 40 | 81% | NS | 100% | NS | ||||
| ≥72 years | 34 | 74% | 84% | ||||||
| Gender | |||||||||
| Male | 41 | 90% | 0.03 | NS | 93% | NS | |||
| Female | 33 | 63% | 94% | ||||||
| Site of primary tumor | |||||||||
| Right colon | 37 | 75% | NS | 88% | NS | ||||
| Left colon | 34 | 82% | 97% | ||||||
| Rectum | 3 | 67% | 100% | ||||||
| TNM stage at diagnosis | |||||||||
| Stage 0/I/II | 42 | 91% | <0.001 | 0.001 | 2.77(1.55-4.96) | 97% | 0.02 | NS | |
| Stage III | 26 | 75% | 88% | ||||||
| Stage IV | 6 | 0% | 80% | ||||||
| Grade of differentiation | |||||||||
| Well | 22 | 95% | 0.03 | NS | 91% | NS | |||
| Moderate | 46 | 77% | 97% | ||||||
| Poor | 6 | 33% | 83% | ||||||
| CEA serum levels | |||||||||
| ≤5 ng/ml | 45 | 80% | NS | 96% | NS | ||||
| >5 ng/ml | 24 | 75% | 92% | ||||||
| Tumor size | |||||||||
| <4 cm | 44 | 83% | NS | 100% | 0.005 | NS | |||
| ≥4 cm | 30 | 70% | 81% | ||||||
| Lymphovascular invasion | |||||||||
| No | 60 | 83% | 0.004 | NS | 95% | NS | |||
| Yes | 14 | 54% | 84% | ||||||
| Perineural invasion | |||||||||
| No | 57 | 83% | 0.03 | NS | 93% | NS | |||
| Yes | 17 | 62% | 93% | ||||||
| Microsatellite instability ¥ | |||||||||
| No | 43 | 72% | NS | 92% | 0.01 | NS | |||
| Yes | 5 | 60% | 40% | ||||||
| BRAF | |||||||||
| Wild type | 69 | 79% | 0.05 | 0.045 | 4.9 (1.04-23.75) | 94% | 0.001 | 0.02 | 4.4 (0.7-28) |
| Mutated | 5 | 60% | 80% | ||||||
| KRAS | |||||||||
| Wild type | 50 | 68% | NS | 90% | NS | ||||
| Mutated | 24 | 77% | 100% | ||||||
| NRAS | |||||||||
| Wild type | 73 | 77% | NS | 93% | NS | ||||
| Mutated | 1 | 100% | 100% | ||||||
| TP53 | |||||||||
| Wild type | 47 | 81% | NS | 93% | NS | ||||
| Mutated | 27 | 77% | 83% | ||||||
| Adjuvant therapy | |||||||||
| No | 40 | 84% | NS | 97% | NS | ||||
| Yes | 34 | 70% | 96% | ||||||
*Results expressed as number of cases (percentage); NS: statistically no significant differences detected, (p >.05); CEA: carcinoembryonic antigen. ¥MSI status variable was not included in the multivariate analysis because MSI information was available only in a subset of 54 cases.